MedTrace Logo

Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

NCT05096390 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-01-25

No results posted yet for this study

Summary

Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Conditions

  • Papillary Renal Cell Carcinoma Type 2

Interventions

DRUG

Axitinib Oral Tablet [Inlyta]

Axitinib 5 up to 10mg twice a day

DRUG

Pembrolizumab Injection [Keytruda]

Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks

Sponsors & Collaborators

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Sylvie NEGRIER, PhD · Centre Leon Berard

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-10-31
Completion
2026-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05096390 on ClinicalTrials.gov